Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$1.28 - $1.73 $2,816 - $3,806
-2,200 Reduced 88.82%
277 $0
Q4 2022

Feb 09, 2023

SELL
$1.16 - $1.8 $404 - $628
-349 Reduced 12.35%
2,477 $3,000
Q3 2022

Nov 09, 2022

SELL
$1.77 - $2.76 $14,691 - $22,908
-8,300 Reduced 74.6%
2,826 $5,000
Q2 2022

Aug 11, 2022

BUY
$1.15 - $3.25 $11,902 - $33,637
10,350 Added 1333.76%
11,126 $28,000
Q3 2021

Nov 12, 2021

SELL
$4.71 - $5.92 $18,430 - $23,164
-3,913 Reduced 83.45%
776 $4,000
Q2 2021

Aug 10, 2021

BUY
$5.32 - $6.53 $18,088 - $22,202
3,400 Added 263.77%
4,689 $26,000
Q1 2021

May 12, 2021

SELL
$2.75 - $6.57 $2,356 - $5,630
-857 Reduced 39.93%
1,289 $7,000
Q4 2020

Feb 10, 2021

SELL
$1.38 - $3.01 $1,255 - $2,739
-910 Reduced 29.78%
2,146 $6,000
Q3 2020

Nov 12, 2020

BUY
$1.58 - $4.77 $4,828 - $14,577
3,056 New
3,056 $5,000
Q2 2020

Aug 13, 2020

SELL
$3.74 - $6.28 $13,673 - $22,959
-3,656 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$2.33 - $12.98 $29,115 - $162,198
-12,496 Reduced 77.37%
3,656 $14,000
Q4 2019

Feb 10, 2020

BUY
$6.75 - $11.15 $90,072 - $148,785
13,344 Added 475.21%
16,152 $173,000
Q3 2019

Nov 12, 2019

BUY
$8.57 - $10.72 $17,414 - $21,783
2,032 Added 261.86%
2,808 $24,000
Q2 2019

Aug 09, 2019

BUY
$7.58 - $10.0 $5,882 - $7,760
776 New
776 $6,000
Q1 2019

May 13, 2019

SELL
$5.81 - $9.37 $51,273 - $82,690
-8,825 Closed
0 $0
Q4 2018

Feb 06, 2019

BUY
$5.75 - $21.85 $50,743 - $192,826
8,825 New
8,825 $57,000
Q1 2018

May 11, 2018

SELL
$20.86 - $26.6 $95,392 - $121,641
-4,573 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$20.9 - $49.36 $95,575 - $225,723
4,573 New
4,573 $113,000
Q3 2017

Nov 15, 2017

SELL
$39.62 - $46.17 $79,240 - $92,340
-2,000 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
2,000
2,000 $71,000

Others Institutions Holding DBVT

About DBV Technologies S.A.


  • Ticker DBVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,776,992
  • Market Cap $175M
  • Description
  • DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...
More about DBVT
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.